

## Public health evidence report following engagement activity

This form is to be completed by the Policy Working Groups Public Health Lead if stakeholders identify potential new evidence during policy development engagement activities. The Public Health Lead will assess the evidence raised to against the Population, Intervention, Comparator and Outcome (PICO) criteria and will record the studies in the appropriate boxes in the 'Outcome for studies suggested during engagement activities' section of this form. In cases where newly identified evidence has a material impact please return the completed form to the Clinical Effectiveness Team (CET).

<b>URN</b>	2320
<b>Policy title:</b>	Arsenic trioxide in combination with all trans retinoic acid for high risk acute promyelocytic leukaemia (age 12 months and over)
<b>CRG:</b>	Chemotherapy
<b>NPOC:</b>	Cancer Programme of Care
<b>Engagement activity</b>	Stakeholder engagement
<b>Date</b>	26/04/2024

<b>Description of comments during engagement (If studies have been suggested please provide a list of references)</b>	<p>NHS England was asked to consider the findings and relevance to the policy proposition of the following studies:</p> <ul style="list-style-type: none"> <li><i>Iland H, Russell N, et al. Characteristics and outcomes of patients with acute promyelocytic leukemia and extreme hyperleukocytosis at presentation. Blood Advances. 2023; 7(11): 2580-2585.</i></li> </ul>
<b>Action taken by Public Health lead</b>	The paper was reviewed against the original PICO criteria for the evidence review that informed the policy proposition.

<b>Outcome for studies suggested during engagement activities</b>	
<b>1. Evidence already identified during the evidence review</b>	The evidence did not meet this criterion.
<b>2. New evidence identified by stakeholders that does not fall within PICO and search methodology</b>	<ul style="list-style-type: none"> <li><i>Iland H, Russell N, et al. Characteristics and outcomes of patients with acute promyelocytic leukemia and extreme hyperleukocytosis at presentation. Blood Advances. 2023; 7(11): 2580-2585. The new evidence is a letter.</i></li> </ul>
<b>3. New evidence identified by stakeholders that falls within PICO and search methodology but does not materially affect the conclusions of the existing evidence review</b>	The evidence did not meet this criterion.
<b>4. New evidence identified by stakeholders that falls within PICO and search methodology, that does materially affect the conclusions of the existing evidence review. Updated evidence review to be undertaken (to be agreed with CET)</b>	The evidence did not meet this criterion.
Completed by:	Public Health Consultant
Date:	26/04/2024